The short version
- A recent study indicates up to 26 percent of active-duty Army personnel could receive low testosterone results under new mandatory screening protocols.
- Medical organizations advise against universal testing due to high variability in hormone levels and the risk of misdiagnosis and overtreatment.
- The Pentagon has proceeded with implementation despite concerns that single measurements often fail to reflect true clinical hypogonadism.
A new study published in the Journal of the American Medical Association suggests that mandatory testosterone screening for Army personnel could identify up to a quarter of active-duty members as having low levels. This finding raises significant concerns among medical professionals regarding the potential for widespread, unnecessary medical evaluations. The research highlights a disconnect between the Pentagon’s recent policy directives and established clinical standards, which generally discourage blanket testing for hormone deficiencies in asymptomatic individuals.
The initiative was announced by Defense Secretary Pete Hegseth in July, with clinical guidance released in September. Under these new rules, mandatory screening applies to male service members aged 30 and older, while younger personnel may opt in. The policy aims to identify potential health issues early, but experts warn that the approach may lead to a cascade of inappropriate testing and diagnoses. Critics argue that this strategy ignores the complex nature of testosterone regulation and the rarity of true clinical hypogonadism.
Researchers from the Pennington Biomedical Research Center in Louisiana and the US Army Research Institute of Environmental Medicine conducted the analysis. They utilized data from a large military health survey involving members at five Army installations. Blood samples were collected between August 2024 and January 2026 from fasting participants during morning hours, a time when testosterone levels are typically highest. The study focused on 479 male active-duty soldiers, excluding those already receiving testosterone treatment to ensure the data reflected baseline conditions.
The sample group was statistically weighted to represent the broader active-duty Army population. Participants had a mean age of approximately 30 years and an average body mass index of 28.4, placing them in the overweight category. The researchers measured total testosterone levels using these samples to estimate how many soldiers would fall below specific clinical thresholds. This methodology allows for a projection of outcomes across the entire force, providing insight into the scale of potential false positives or incidental findings.
Using the Pentagon’s specified threshold of less than 300 ng/dL, which aligns with recommendations from the American Urological Association, the study estimates that about 26 percent of active-duty Army members would receive a result indicating low testosterone. If the Centers for Disease Control and Prevention’s lower harmonized reference cutoff of 264 ng/dL were applied, approximately 15 percent of service members would still be flagged. These figures are substantially higher than the estimated prevalence of clinical hypogonadism, which affects no more than one percent of men.
Medical experts emphasize that testosterone levels are highly variable and influenced by numerous factors beyond pathological conditions. Levels can fluctuate based on age, time of day, obesity, illness, physical stress, poor sleep, trauma, and medication use. Because these variables can cause temporary dips in hormone levels, a single low measurement does not necessarily indicate a chronic medical condition. The Endocrine Society and other professional bodies recommend that evaluations be triggered by patient-reported symptoms rather than universal screening.
The study found that the likelihood of receiving a low result increased with both age and body mass index. Among men under 30, nearly 20 percent had measurements below the threshold, while one-third of those aged 30 and older showed low levels. The researchers note that distinguishing between an isolated low value and clinically significant hypogonadism is crucial, as testosterone replacement therapy carries potential adverse effects and requires long-term commitment. Misdiagnosis could lead to overtreatment, including risks such as infertility.
Each positive screening result under the new policy will require thorough follow-up procedures. This includes repeat testing, further medical evaluation, and counseling on modifiable lifestyle factors like weight loss and sleep improvement. The researchers argue that the current norm of symptom-driven diagnosis is more reliable for identifying true cases of male hypogonadism, which often stems from rare genetic conditions or pituitary gland issues. The mandatory screening program proceeds despite these warnings, leaving uncertainty about its long-term impact on military readiness and individual health outcomes.
The divergence between the study’s findings and clinical recommendations underscores the challenges of implementing broad health screenings in a large population. While the intent may be to proactively address health concerns, the risk of generating anxiety and unnecessary medical interventions remains high. As the Pentagon moves forward with this policy, the military medical community faces the task of managing a potential influx of referrals for conditions that may not exist. The situation highlights the tension between administrative health initiatives and evidence-based medical practice.
Future implications of this policy remain unclear, particularly regarding how many younger soldiers will choose to opt in and how the system will handle the volume of follow-up care required. The study does not assess symptoms, which limits its ability to predict clinical outcomes accurately. However, it provides a clear indication that universal screening may flag a significant portion of the force for conditions they do not have. This raises questions about resource allocation and the potential for harm from unnecessary medical interventions in an otherwise healthy population.
Sources behind this briefing
Go to the original reporting
- Ars Technica↗Hegseth’s dubious low-T screening may flag up to 25 percent of the Army
